Want to see DE:SBS full AI Analyst Report?
Total Valuation
STRATEC Biomedical has a market cap or net worth of €263.18M. The enterprise value is €300.91.
Market Cap€263.18M
Enterprise Value€300.91
Share Statistics
STRATEC Biomedical has 12,157,841 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,157,841
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
STRATEC Biomedical’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.10%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)-0.10%
Return on Capital Employed (ROCE)0.02
Revenue Per Employee181.39K
Profits Per Employee-174.98
Employee Count1,383
Asset Turnover0.57
Inventory Turnover1.65
Valuation Ratios
The current PE Ratio of STRATEC Biomedical is ―. STRATEC Biomedical’s PEG ratio is 11.11.
PE Ratio―
PS Ratio1.09
PB Ratio1.15
Price to Fair Value1.15
Price to FCF-28.10
Price to Operating Cash Flow7.75
PEG Ratio11.11
Income Statement
In the last 12 months, STRATEC Biomedical had revenue of 250.86M and earned -242.00K in profits. Earnings per share was -0.02.
Revenue250.86M
Gross Profit64.22M
Operating Income8.59M
Pretax Income4.85M
Net Income-242.00K
EBITDA27.19M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was 35.05M and capital expenditures -8.72M, giving a free cash flow of 26.33M billion.
Operating Cash Flow35.05M
Free Cash Flow26.33M
Free Cash Flow per Share2.17
Dividends & Yields
STRATEC Biomedical pays an annual dividend of €0.6, resulting in a dividend yield of 2.68%
Dividend Per Share€0.6
Dividend Yield2.68%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.45
52-Week Price Change-7.88%
50-Day Moving Average19.37
200-Day Moving Average19.34
Relative Strength Index (RSI)66.50
Average Volume (3m)15.55K
Important Dates
STRATEC Biomedical upcoming earnings date is Nov 12, 2026, Before Open (Confirmed).
Last Earnings DateAug 14, 2026
Next Earnings DateNov 12, 2026
Ex-Dividend Date―
Financial Position
STRATEC Biomedical as a current ratio of 3.97, with Debt / Equity ratio of 48.53%
Current Ratio3.97
Quick Ratio1.86
Debt to Market Cap0.44
Net Debt to EBITDA4.01
Interest Coverage Ratio2.13
Taxes
In the past 12 months, STRATEC Biomedical has paid 5.09M in taxes.
Income Tax5.09M
Effective Tax Rate1.05
Enterprise Valuation
STRATEC Biomedical EV to EBITDA ratio is 14.05, with an EV/FCF ratio of -39.33.
EV to Sales1.52
EV to EBITDA14.05
EV to Free Cash Flow-39.33
EV to Operating Cash Flow-882.16
Balance Sheet
STRATEC Biomedical has €19.03M in cash and marketable securities with €115.72M in debt, giving a net cash position of -€96.69M billion.
Cash & Marketable Securities€19.03M
Total Debt€115.72M
Net Cash-€96.69M
Net Cash Per Share-€7.95
Tangible Book Value Per Share€10.64
Margins
Gross margin is 23.57%, with operating margin of 3.43%, and net profit margin of -0.10%.
Gross Margin23.57%
Operating Margin3.43%
Pretax Margin1.93%
Net Profit Margin-0.10%
EBITDA Margin10.84%
EBIT Margin3.43%
Analyst Forecast
The average price target for STRATEC Biomedical is €28.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€28.00
Price Target Upside42.13% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast―